Centrient Pharmaceuticals* (Centrient *) becomes member of the United Nations Global Compact (UNGC), strengthening commitment to ethical and sustainable business growth
- Centrient joins the UN Global Compact, aligning its sustainability commitments with global standards
- By joining the world’s largest corporate sustainability initiative, Centrient reinforces its dedication to responsible business practices in human rights, labor standards, environmental stewardship, and anti-corruption.
Centrient, a key global business-to-business supplier of sustainable, enzymatic antibiotics, next-generation statins, and anti-fungals, announces today that it has joined the United Nations Global Compact (UNGC), the world’s largest corporate sustainability initiative.
By joining the UNGC, Centrient strengthens its commitment to upholding globally recognised standards in human rights, labor, environmental sustainability, and anti-corruption.
"Joining the UN Global Compact is a natural extension of how we operate at Centrient,” said Rex Clements, CEO of Centrient. “As one of the world’s leading producers of antibiotics, we know that doing business responsibly isn’t optional—it’s essential. This step reflects our determination to advance sustainable manufacturing, protect public health, and contribute to a healthier future for people and the planet.”
Centrient’s commitment to responsible business practices is already reflected in its approach to Environmental, Social, and Governance (ESG) topics. The company holds Minimized AMR certification from BSI for responsible antibiotic manufacturing at its Santa Perpetua site in Spain and has set near-term climate targets validated by the Science Based Targets initiative (SBTi). As part of its commitment to fighting antimicrobial resistance (AMR) – one of the top 10 health risks according to the World Health Organization – Centrient was a founding member of the AMR Industry Alliance. Its Santa Perpetua site has been independently verified against rigorous standards for controlling antibiotic manufacturing emissions and preventing environmental contamination — a critical step in fighting antimicrobial resistance.
On the social side, Centrient aims to improve access to essential medicines for 1.5 billion patients, while advancing diversity, equity, and inclusion across its global workforce. Employees are encouraged to initiate and participate in community action initiatives, ranging from reforestation efforts, education, supporting the most vulnerable groups, and well-being activities. Our Global Purpose Platform – set up five years ago – is employee-led and inspires employees to take part in community acitivites.
In governance, Centrient enforces high standards of ethics and accountability, guided by its Code of Conduct and Human Rights policy, which aligns with core ILO conventions and the UN Declaration of Human Rights.
“Joining the UN Global Compact builds on the work already underway at Centrient,” said Jean-Giraud, Chief Human Resources Officer, Communications and ESG Officer. “It brings additional structure and accountability to integrating sustainability and ethics into our day-to-day operations. It’s about doing what’s right — and doing it consistently.”
Through the UN Global Compact, Centrient will continue to align its work with the UN Sustainable Development Goals (SDGs), reinforcing its responsibility to people, the planet, and long-term business resilience.
About the UN Global Compact
The United Nations Global Compact (UNGC) is the world’s largest corporate sustainability initiative, uniting companies worldwide to adopt sustainable and socially responsible policies. By advocating for universal principles in human rights, labor, environment, and anti-corruption, the UNGC fosters collaboration between businesses, governments, and civil society to advance global goals, including the United Nations Sustainable Development Goals (SDGs).
-----------------------------------------------------------------------------------------------------------
About Centrient Pharmaceuticals
Centrient Pharmaceuticals is the global business-to-business leader in sustainable, enzymatic antibiotics, next-generation statins, and anti-fungals. We are a pharmaceutical company with a clear Purpose: to improve lives through innovative and sustainable manufacturing of medicines - saving the lives of millions of people around the world annually. Regarding our portfolio, we produce and sell intermediates and active pharmaceutical ingredients (APIs), as well as finished dosage forms (FDFs). Centrient Pharmaceuticals is a Board Member of the AMR Industry Alliance and a long-time advocate for industry responsibility in manufacturing. For more information, please visit www.centrient.com, www.linkedin.com/company/centrient or contact Centrient Pharmaceuticals Global Communications and ESG Director, Neil Moorhouse. E-Mail: neil.moorhouse@centrient.com.
*(1) “Centrient Pharmaceuticals”, “Centrient” in this content are sometimes used for convenience where references are made to Centrient International Pharmaceuticals B.V, and or one or more of its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to Centrient Pharmaceuticals International B.V. and or one or more of its subsidiaries in general or to those who work for them. These terms are also used where no useful purpose is served by identifying the particular entity or entities. “Subsidiaries”, “Centrient subsidiaries” and “Centrient companies” as used in this content refer to entities over which Centrient Pharmaceuticals International B.V. either directly or indirectly has control. The term “Centrient interest” is used for convenience to indicate the direct and/or indirect ownership interest held by Centrient Pharmaceuticals International B.V. in an entity or unincorporated joint arrangement, after exclusion of all third-party interest.